Third Bridge provides integrated research solutions for the world’s top investors and business leaders. Our expanding suites of products can help you drive change, putting crucial insights, value chain maps and experts at your fingertips.
The following transcript is generated from Third Bridge Primers, providing fundamental information on privately held companies from unique human insights, enabling investors to quickly understand a company in early-stage research.
Submit your details to gain access to our premium content. If you would like to discuss our coverage of companies and sectors and how we can help you move faster and with greater conviction, please contact us today.
Specialist
Former Senior Executive at Real Chemistry
Agenda
- Company Overview
- Market Growth & Drivers
- Competitive Landscape
- Company Performance & Growth Potential
Questions
1.
Can you briefly describe what Real Chemistry does and what products and services it provides?
2.
What is the value proposition of the products and services that Real Chemistry offers?
3.
What is the full range of industries and business sizes that could use these products and services that Real Chemistry offers?
4.
Within this range we’ve discussed, can you profile the typical target customers of Real Chemistry across industries and business sizes?
5.
Can you provide a few examples of Real Chemistry’s publicly-known customers?
6.
What are the key regions that Real Chemistry derives revenue from? What is the revenue share of each?
7.
From a revenue stream perspective, what are the core segments of Real Chemistry? What are its core products and service offerings?
8.
What is the relative size of each segment in the following ranges of Real Chemistry’s total revenue – 0-10%, 11-20%, 21-30%, 31-40%, etc?
9.
What is the revenue model for each of these segments – transactional, reoccurring or recurring?
10.
Can you provide a typical use case for each of Real Chemistry’s segments?
11.
You mentioned analytics is the fastest-growing right now. Which segment do you anticipate to be the fastest-growing and could potentially drive the largest share of Real Chemistry’s revenue in the future?
12.
How would you label the market which Real Chemistry operates within?
13.
What has the average annual medical marketing and communications market growth rate been over the past three years – less than 0%, 0-5%, 6-10%, 11-20% or greater than 20%?
14.
What do you think have been the top 1-2 key drivers of this three-year historical market growth?
15.
What do you think the average annual market growth rate will be over the next three years?
16.
What do you think will be the 1-2 key drivers of future growth for the market?
17.
To what degree do you think this industry is correlated to economic cyclicality? Is it counter-cyclical, very cyclical, somewhat cyclical, somewhat resilient or resilient? Why?
18.
Based on public information, what impactful technological evolutions or innovations should we anticipate over the next 3-5 years in this industry?
19.
Are there any downside risks that you believe might materially impact the market growth over the next three years in this industry?
20.
What would you say are downside risks other than potential regulation or tech disruption?
21.
How fragmented do you consider the medical marketing and communications industry to be? Would you say it is a monopoly or are there 2-5 strong players? Is it fragmented or highly fragmented?
22.
How protected is this market? What are the barriers to entry or to scale in this market?
23.
Who are Real Chemistry's top three direct competitors?
24.
How would you rank each of these players in terms of market share?
25.
What was the revenue for Real Chemistry and IPG for the last financial year, in a USD 100m range? Omnicom, Publicis and WPP are public companies.
26.
What was the revenue growth for Real Chemistry and IPG in the last financial year in a percentile range?
27.
What have been the drivers of growth for each of these players – organic, acquisition-based or mixed?
28.
In your opinion, what is the benchmark EBITDA margin for the players mentioned above? How profitable do you think these players are – 0-10%, 11-20%, 21-30%, etc?
29.
What are the approximate range EBITDA for each of these players? Would you say they are on, above or below industry?
30.
How do you think these players differentiate themselves? What are the differentiating factors or unique selling propositions? Let’s start with Real Chemistry.
31.
What do you think are the customers' top three purchasing criteria? How do you think the criteria rank in terms of importance?
32.
How important do you think price is to customers in this market? Would you say it is commoditised, somewhat commoditised or not commoditised? Why?
33.
What do you think have been the key drivers of historical growth for Real Chemistry?
34.
How fast do you think Real Chemistry could grow over the next three years in terms of an annual growth rate – less than 0%, 0-5%, 6-10%, 11-20% or greater than 20%?
35.
In your opinion, what could be some of the interesting ways to grow Real Chemistry? If you were running it, firstly, how would you look at organically improving its growth profile?
36.
How would you look at improving the margins of Real Chemistry if you were running the company?
37.
What would you do to drive Real Chemistry’s growth in terms of M&A?
38.
Based on its publicly announced acquisitions, how would you describe Real Chemistry’s M&A strategy?
39.
In your opinion, could it make sense for Real Chemistry to acquire, merge with or be acquired by any other players in or outside the space?
40.
What would you say are the 1-2 biggest risks faced by Real Chemistry?
41.
In your opinion, is there anything that the market does not properly understand about Real Chemistry? Are there any common misconceptions about it in the market?
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited
